Novartis Statement on Reported Case of PML Novartis has been informed of a patient with progressive multifocal leukoencephalopathy [...]
FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS BLA Acceptance Follows [...]
Mallinckrodt Research Fellowship Award Program Announcement Mallinckrodt Pharmaceuticals is pleased to announce the Research Fellowship [...]
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b) Offers [...]
International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction Many Factors Influence Patient [...]
TECFIDERA® (Dimethyl Fumarate) Data Reinforce Strong, Sustained Efficacy for Newly-Diagnosed MS Patients TECFIDERA Provides Robust and [...]
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of [...]
Teva Neuroscience & Access Health Team Up for Special MS Awareness Show: Thursday, March 5 As Multiple Sclerosis Awareness Week [...]
Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis Phase 1 trial [...]
First MS Patients in the U.S. Receive Genzyme’s Lemtrada Following FDA Approval – Lemtrada now available in the U.S. two weeks post [...]